🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the effort against drug-resistant strains of the infection, according to researchers.

A Worldwide Health Concern

The sexually transmitted infection are escalating globally, with figures suggesting in excess of 82 million instances per year. Notably increased rates are observed in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the context of rising global incidence, the spread of superbugs and the very limited treatment choices currently available.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The WHO has listed it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Secure Approval

One new antibiotic, also known as a brand name, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Researchers hope that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the drug firm Innoviva to develop it.

“This approval represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Clinical Trial Data and Worldwide Availability

According to findings detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which uses an injection and a pill. The research involved nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to make available and distribute the drug in many regions with limited resources.

Clinicians treating patients have expressed hope. The availability of a one-pill regimen of this kind is described as a "critical tool" for public health efforts. This is viewed as crucial to reduce the burden of the infection for people and to prevent the spread of extremely resistant gonorrhoea around the world.